Moderna is trading 4.03% higher at $251.84 on October 21 as investors focus on positive Phase 3 results for its personalized melanoma vaccine with Merck. - The company plans to seek FDA review; detailed trial data are expected at the October 24 ESMO meeting. - TD Cowen raised its price target to $90 from $40 and maintained a Hold rating. - Available coverage does not establish that any single update explains the exact intraday gain.